Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., specializes in providing custom research and development services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business of the company includes providing small molecule drug intermediates and custom R&D production services for new drug development projects from well-known global pharmaceutical companies [2][8]. - The company's revenue composition consists of 69.58% from fluorinated CDMO business, 29.10% from non-fluorinated CDMO business, 0.82% from trade and others, and 0.51% from technical services [8]. - As of July 31, the number of shareholders increased by 4.09% to 14,400, with an average of 3,939 circulating shares per person, a decrease of 3.93% [8]. Group 2: Financial Performance - For the first quarter of 2025, the company achieved a revenue of 176 million yuan, representing a year-on-year growth of 41.83%, and a net profit attributable to shareholders of 47.42 million yuan, up 183.24% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 61.18% of total revenue [4]. - The stock price has shown a slight increase of 0.25% with a trading volume of 378 million yuan and a turnover rate of 16.14%, leading to a total market capitalization of 4.914 billion yuan [1].
金凯生科涨0.25%，成交额3.78亿元，今日主力净流入200.37万